focus -WSS

focus

author：focus 2025-10-02 18:42:13 - browse：46882

Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble — coverage from STAT — Under a microscope, human prostate cancer cells, colorized in blue, appear in an air bubble. Adobe

An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some signs of efficacy in prostate cancer patients, newly released data show, but four participants in the trial died.

The drug, JNJ-6420, is designed to treat metastatic castration-resistant prostate cancer by delivering radioactive isotopes directly to cancer cells. Interest in such radiopharmaceuticals has skyrocketed following the approval of Pluvicto, which also treats prostate cancer.

In the Phase 1 data reported ahead of the American Society of Clinical Oncology meeting next week, 18% of participants on a mid-level dose of Johnson & Johnson’s treatment had a complete or partial response. For comparison, approximately 29.8% of the subjects in a Phase 3 trial of Pluvicto responded to the treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

WSS

Live blog: Hearing on CRISPR

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Resistance to opioid

AMAs digital advisors table RPM coding reform proposal, again

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Medicare must police algorithms in Medicare Advantage, Dems say

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Travis Kelce and the trap of celebrity vaccine endorsements

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Brain injuries and the importance of a second opinion

Malaria cases in Florida and Texas: Here’s what you need to know

Artificial intelligence use in health care faces greater scrutiny in 2024

Supreme Court strikes down use of affirmative action

How neuroscience research could help beat back brain cancer

Apple is now the first public company to be valued at $3 trillion

Juul documents reveal insider tactics on political lobbying

focus

What is microchimerism and how does it affect maternal health?

ACIP vaccine advisory panel sees its vacancies filled

Prime Medicine says its gene editing passes test in monkeys

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Tome Biosciences co

Coloradans with cystic fibrosis could lose access to Trikafta

knowledge

knowledge

entertainment

entertainment